Scientists make advance in cancer research
The most advanced version of vβ3-integrin antagonists failed clinical trials to treat aggressive forms of brain cancer. But research published today in the American Heart Association’s journal Circulation Research shows that targeting the protein in question could still be vital in stopping the growth of tumors. Not least because the drugs targeting it cause minimal side effects compared to other drugs — which can cause bleeding in the gut and high blood pressure. tumors must recruit their own blood supply to grow beyond a very small size…